A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Dana-Farber Cancer Institute
Celgene
Qilu Pharmaceutical Co., Ltd.
University of Miami
Children's Hospital Medical Center, Cincinnati
Massachusetts General Hospital
Karyopharm Therapeutics Inc
Dana-Farber Cancer Institute
Massachusetts General Hospital
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Assistance Publique - Hôpitaux de Paris